Clearside Biomedical (CLSD) has released an update to notify the public and investors about a regulation fd disclosure.
The Company recently announced the pricing of its Registered Direct Offering, emphasizing that the provided information won’t be considered filed under the Securities Exchange Act. They included forward-looking statements about the offering’s completion, highlighting potential risks that might influence the actual results, such as market conditions and closing conditions. These statements are made with the understanding that they are based on current beliefs and subject to change, and should be viewed with caution due to the inherent uncertainties.
For further insights into CLSD stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
